Role of acetylcholine spasm provocation test as a pathophysiological assessment in nonobstructive coronary artery disease

Satoru Suzuki1 · Koichi Kaikita1 · Eiichiro Yamamoto1 · Hideaki Jinnouchi2 · Kenichi Tsujita1

Received: 7 October 2020 / Accepted: 8 October 2020 / Published online: 27 October 2020
© The Author(s) 2020, corrected publication 2020

Abstract
Coronary angiography (CAG) sometimes shows nonobstructive coronary arteries in patients with suspected angina or acute coronary syndrome (ACS). The high prevalence of nonobstructive coronary artery disease (CAD) in those patients has recently been reported not only in Japan but also in Western countries, and is clinically attracting attention. Coronary spasm is considered to be one of the leading causes of both suspected stable angina and ACS with nonobstructive coronary arteries. Coronary spasm could also be associated with left ventricular dysfunction leading to heart failure, which could be improved following the administration of calcium channel blockers. Because we rarely capture spontaneous attacks of coronary spasm with electrocardiograms or Holter recordings, an invasive diagnostic modality, acetylcholine (ACh) provocation test, can be useful in detecting coronary spasm during CAG. Furthermore, we can use the ACh-provocation test to identify high-risk patients with coronary spasm complicated with organic coronary stenosis, and then treat with intensive care. Nonobstructive CAD includes not only epicardial coronary spasm but also microvascular spasm or dysfunction that can be associated with recurrent anginal attacks and poor quality of life. ACh-provocation test could also be helpful for the assessment of microvascular spasm or dysfunction. We hope that cardiologists will increasingly perform ACh-provocation test to assess the pathophysiology of nonobstructive CAD.

Keywords 
Coronary spasm · Acetylcholine provocation test · Nonobstructive coronary artery disease · Microvascular spasm

Introduction
We often perform percutaneous coronary intervention (PCI) with coronary stent implantation for significant organic coronary artery stenosis with induced myocardial ischemia. PCI has become a useful treatment for relief of chest symptom in patients with significant coronary organic stenosis. However, coronary angiography (CAG) sometimes shows nonobstructive coronary arteries that do not need revascularization in patients with suspected angina [1–11]. Indeed, more than 50% of stable patients with suspected angina undergoing CAG had angiographically nonobstructive coronary arteries that did not require revascularization [4, 10]. In addition, despite the high prevalence of obstructive coronary artery disease (CAD) in acute myocardial infarction (AMI), up to 13% of AMI patients had nonobstructive CAD (myocardial infarction with nonobstructive coronary arteries [MINOCA]) [6, 7, 12–14]. This high prevalence of nonobstructive CAD has recently been reported not only in Japan but also in Western countries [6, 10, 15, 16]. Thus, nonobstructive CAD is attracting clinical attention because it may be associated with future cardiovascular events [1, 2, 4–7, 17]. Coronary spasm is considered to be one of the leading causes of both stable angina with nonobstructive CAD and MINOCA (the others being microvascular spasm, spontaneous coronary artery dissection, coronary artery embolism, myocardial bridging, and Takotsubo cardiomyopathy) [1, 5–7, 10, 11, 18, 19] (Fig. 1).

Yasue and coworkers previously reported that the intracoronary injection of acetylcholine (ACh) is a useful test for the provocation of coronary spasm [20–23]. Since
these reports, angina pectoris caused by coronary spasm is now referred to as "coronary spastic angina" or "vasospastic angina" [24–35], and variant angina is regarded as one aspect of the wide spectrum of myocardial ischemic syndromes caused by coronary spasm [24]. Although the etiologic mechanisms of stable angina and acute coronary syndrome (ACS) in patients with
nonobstructive CAD remain obscure, coronary spasm can play an important role in the pathogenesis of these diseases [1, 5–7, 16, 19, 24, 25, 36, 37]. Recent studies reported that coronary spasm could also be associated with left ventricular dysfunction leading to heart failure [38–41]. ACh-provocation test might be useful as a diagnostic tool of nonobstructive CAD, and might play a key role in the assessment of its pathophysiology [1, 5–7, 16, 21, 22, 24, 42].

In this review article, we discuss the significance of ACh-provocation test as a tool for pathophysiological evaluation in nonobstructive CAD including coronary spasm.

Use of ACh in the coronary spasm provocation test

Coronary spasm usually occurs at rest, particularly from midnight to early morning [24–27]. Coronary spasm can be induced even by mild exercise in the early morning but is not usually induced in the afternoon even by strenuous exercise [24, 31–33]. Based on these reports, a circadian rhythm can be associated with the activity of coronary spasm, although the precise mechanisms of circadian variation in coronary spasm have not yet been elucidated. Our previous studies reported that coronary spasm can be induced by subcutaneous injection of methacholine, an analog of ACh that stimulates the parasympathetic nervous system, and that this attack can be suppressed by the parasympatholytic agent atropine, in patients with variant angina [22, 33, 43–47]. Activity of the parasympathetic nervous system is enhanced at rest and is suppressed by exercise [48]. At that time, we hypothesized that activity of the parasympathetic nervous system might be involved in the pathogenesis of variant angina or coronary spasm, and showed that the intracoronary injection of ACh could be useful for inducing coronary spasm [22, 23].

ACh usually causes vasodilation by releasing nitric oxide from the endothelium, and intracoronary injection of ACh in humans provokes coronary vasodilation in young healthy subjects, whereas it causes vasoconstriction in patients with coronary endothelial dysfunction such as coronary atherosclerosis [49–51]. The coronary arteries in patients with coronary spasm are highly sensitive to the vasoconstrictor effect of intracoronary injection of ACh, resulting in spasm [52]. Our previous reports showed that the sensitivity and specificity of the intracoronary injection of ACh were very high in variant angina and that multivessel coronary spasm was often observed in patients with variant angina following intracoronary injection of ACh [20, 21]. ACh-provoked coronary spasm is of short duration, probably because ACh is rapidly degraded by acetylcholinesterase in vivo [22]. In addition, previous studies reported low rates of complications with ACh-provocation test during CAG [53–55]. Thus, ACh-provocation test could be a safe and reliable method to diagnose coronary spasm during CAG [8, 24, 25, 47, 53–61]. Nonobstructive CAD includes not only angina with epicardial coronary spasm but also microvascular spasm [4–7, 62]. However, the coronary microcirculation is not easily visualized, while the epicardial coronary arteries are easily visualized by CAG or computed tomography angiography (CTA). Microvascular spasm or dysfunction can be assessed partially from the results of both coronary blood flow (CBF) during ACh-provocation test and adenosine triphosphate-induced coronary flow reserve (ATP-CFR), which is a non-endothelium-dependent coronary reactivity test [4, 10, 63–67]. The ACh-provocation test can be useful to assess the comprehensive pathophysiology of total coronary arteries including epicardial coronary arteries and microvascular lesions.

Ovisot® (ACh chloride) was approved as an inducer of coronary spasm during CAG in 2017 in Japan. This approval will lead to more testing for provocation of coronary spasm in Japan, adaptation of the treatment based on the patient’s progress, and detailed pathophysiological evaluation of nonobstructive CAD including coronary spasm.

In addition to ACh, ergonovine (ER) is also useful for pharmacological provocation of coronary spasm. According to the Japanese Circulation Society (JCS) Guidelines [25], the intracoronary injection of ER provocation test during CAG is also recommended in patients with suspected coronary spasm. In the coronary arteries of patients with coronary spasm, it is thought that intracoronary injection of ACh can provoke coronary spasm via muscarinic receptors, whereas intracoronary injection of ER can provoke it via serotonin receptors [24, 52, 56, 68, 69]. Based on these observations, it is suggested that there may be several mechanisms by which the coronary artery causes coronary spasms [22, 23, 29, 56, 70–73]. A previous study reported that ACh provoked more diffuse and distal coronary spasms, whereas ER provoked more focal and proximal ones [74], indicating that ACh-provocation test might not provoke coronary spasm in all patients with coronary spasm. Further studies of the mechanisms underlying the difference between provoked-spasm sites in the ACh and ER provocation tests are needed.

Diagnosis of coronary spasm by the ACh-provocation test

Studies in Japan have made many contributions to the pathophysiology, diagnosis, and treatment of coronary spasm, leading to the development of the Guidelines for Diagnosis and Treatment of Patients with Vasospastic Angina by the JCS [25, 54, 59, 75–78]. Although previous reports indicated that the prevalence of coronary spasm has been less
in Western countries than in Asian (including Japan), recent reports have showed that the prevalence of coronary spasm in Western countries may be higher than indicated in previous reports [6, 10, 15, 79, 80]. According to the JCS Guidelines for Vasospastic Angina (Coronary Spastic Angina) [25] (Fig. 2), we can consider a definitive diagnosis of coronary spasm when one of the following is true: (1) ischemic change is clearly observed on the ECG during attacks; (2) the ECG findings during an attack of coronary spasm are borderline but a clear finding of myocardial ischemia or coronary spasm is obtained in examinations (ACh- or ER-induced coronary spasm provocation test during CAG or hyperventilation test) and the patient has a history and symptoms during attacks that are consistent with coronary spasm; or (3) if there is no ECG change during a spontaneous attack of coronary spasm or if ECG examination has not been performed, at least one of the reference items (Fig. 2) is met, and this examination reveals a clear finding of myocardial ischemia or coronary spasm. A positive finding for coronary spasm on CAG in the ACh- or ER-induced coronary spasm provocation test is defined as “transient, total, or sub-total occlusion (> 90% stenosis) of a coronary artery with signs/symptoms of myocardial ischemia (anginal chest pain and ischemic ECG change)”. Because we do not often observe a spontaneous attack of coronary spasm in which ischemic change is clearly documented on the ECG, adding the invasive diagnostic ACh-provocation test can be useful to diagnose coronary spasm during CAG in patients with suspected coronary spasm [5, 16, 25].

We and others previously reported different patterns of angiographic changes including focal (total or sub-total obstruction) and diffuse spasm (severe diffuse vasoconstriction) during the spasm provocation test [52, 59, 60, 79, 81, 82]. In a retrospective, observational, and single-center 20-year study of consecutive patients who underwent the ACh-provocation test in our institution [54] (Fig. 3), ACh-provoked coronary spasm was observed in 873 (50%) of 1760 patients with typical or atypical angina-like chest pain (with 487/873 [56%] male, 386/873 [44%] female). Among the ACh-provoked coronary spasm patients, the number of focal spasms was 511/873 (59%) (with 343/511 [67%] male, 168/511 [33%] female), while the number of diffuse spasms was 362/873 (41%) (with 144/362 [40%] male, 218/362 female [60%]). We showed that female sex and low comorbidity of epicardial coronary artery stenosis (≥ 75%) were correlated with the ACh-provoked diffuse spasm pattern in patients with coronary spasm, and that ACh-provoked diffuse coronary spasm had a better prognosis than focal spasm for major adverse cardiac events (MACE). Another previous report showed that mixed (focal + diffuse) type multivessel coronary spasm had an important association with MACE [59]. These results suggest that we need to perform an ACh-provocation test to identify the subtype of ACh-provoked coronary spasm and to assess the risk of future cardiovascular events. Although the ACh-provoked diffuse spasm...
Role of acetylcholine spasm provocation test as a pathophysiological assessment in...

spasm pattern is not at present included as a positive criterion for the ACh-provocation test in the JCS Guidelines [25], we may need to establish additional diagnostic criteria for coronary spasm in the future.

According to the JCS Guidelines, ACh-provocation test is not recommended during emergent CAG in patients with ACS [25]. The American Heart Association and American College of Cardiology guidelines also indicated that intracoronary provocative tests may be undertaken after ACS has become stable [83, 84]. However, some recent reports showed that during emergent CAG, ACh-provocation test was safely performed in ACS patients with nonobstructive culprit lesions and was useful to diagnose coronary spasm-induced ACS in those patients [6, 7, 85]. Nonetheless, the indication for the ACh-provocation test during emergent CAG in ACS patients remains controversial.

Epicardial coronary spasm can be seen angiographically during the ACh-provocation test; however, it is unclear whether the coronary spasm causes myocardial ischemia. For this reason, we usually measure myocardial lactate production in the coronary circulation during ACh-provocation tests in the left coronary artery as a supporting diagnostic marker for the evaluation of coronary spasm-induced myocardial ischemia [25, 86]. Our previous reports showed that ACh-provoked myocardial lactate production was more frequently observed in patients with diffuse spasm than in those with focal spasm [54], and that female sex, diabetes, and the $−786T/C$ single nucleotide polymorphism in endothelial nitric oxide synthase gene were associated with ACh-provoked myocardial lactate production in patients with coronary spasm [86]. Evaluation of the myocardial lactate production during ACh-provocation test might improve our diagnostic approach to nonobstructive CAD and our understanding of its pathophysiology.

**ACh-provoked coronary spasm and organic coronary artery stenosis**

Coronary spasm can occur at sites of varying arteriosclerosis severity. We and others previously reported that coronary spasm could be associated with the progression of atherosclerosis [87–91]. Patients with coronary spasm are generally considered to have a good prognosis for cardiovascular...
events [54, 92–95]. On the other hand, the presence of organic coronary artery stenosis could be a significant prognostic factor for cardiovascular events in patients with coronary spasm [15, 78, 96–98]. Previous study reported that intermediate fixed coronary artery stenosis at the site of spasm provoked by ER could be a prognostic factor for cardiovascular events in patients with coronary spasm [99]; however, this study did not compare patients with coronary spasm occurring at sites other than the site of significant stenosis to patients with coronary spasm but without stenosis.

We previously reported that ACh-provoked coronary spasm occurring at the site of significant coronary artery stenosis was a more significant prognostic factor for MACE than ACh-provoked coronary spasm occurring at the site other than the site of organic stenosis, suggesting that coronary spasm can be associated with the cause of MACE when the coronary spasm occurs at the site of organic stenosis [100, 101]. This finding emphasized the need to identify the site of coronary spasm in patients with significant organic coronary artery stenosis to provide optimal medical treatment for coronary spasm patients with atherosclerotic disease.

At present, we often perform PCI with coronary stent implantation for significant organic coronary artery stenosis. Coronary spasm occurring after coronary stent implantation has become a clinical problem [25, 102–107]. A previous report showed that excessive coronary vasoconstriction of PCI-treated coronary arteries in response to intracoronary injection of ACh was more frequent in patients treated with bare metal stents (BMS) than in those treated only with balloon angioplasty, suggesting that endothelial dysfunction induced by PCI was involved in the progression of atherosclerosis [108]. Furthermore, some reports showed that following intracoronary injection of ACh, vasoconstriction in segments adjacent to stents was more severe for drug-eluting stents (DES) than for BMS-treated coronary arteries [109, 110]. Regarding this point, we reported that second-generation DES occurred fewer cardiovascular events related to coronary spasm than first-generation DES or BMS because of the advanced design features of second-generation DES (higher biocompatibility and/or biodegradable polymers) [103, 104]. These studies suggested that ACh-provocation test could be useful to assess the coronary vasoconstrictor response after coronary stent implantation (Fig. 4).

Significance of the ACh spasm provocation test in left ventricular dysfunction

Recent studies reported that epicardial coronary spasm could be associated with left ventricular (LV) dysfunction [38–41]. We previously reported a case in which asymptomatic coronary spasm may have caused irreversible cardiac damage leading heart failure, suggesting that the presence or absence of coronary spasm in heart failure patients should be clarified to determine therapeutic strategy [40]. Several studies reported that multivessel or diffuse coronary spasm could lead to LV dysfunction such as dilated cardiomyopathy (DCM), and that the LV dysfunction in these patients

![Fig. 4](image-url)
LV dysfunction and heart failure [4, 19, 54, 113–117]. It is likely to have myocardial fibrosis or degeneration on cardiac magnetic resonance imaging (MRI) or endomyocardial biopsy than patients in the ACh-negative (no coronary spasm) group. In the ACh-positive group, LV dysfunction was significantly improved following the administration of CCBs. This study suggested that repeated coronary spasm or persistent increase of coronary vasotonus leading to LV dysfunction might occur, and that CCBs might improve LV dysfunction by reducing the coronary spasm or coronary vasotonus.

On the other hand, ACh-provoked coronary vasomotor abnormality (e.g. epicardial coronary spasm or microvascular spasm) in our previous study was shown to be closely associated with myocardial fibrosis (expressed as late gadolinium enhancement in cardiac MRI) in patients with heart failure and without organic coronary artery stenosis [111, 112]. Coronary vasomotor abnormalities such as coronary spasm or microvascular spasm could affect the development of nonobstructive CAD, and might be associated with LV dysfunction and heart failure [4, 19, 54, 113–117]. It is suggested that coronary vasomotor abnormality diagnosed by ACh-provocation test could be involved in myocardial fibrosis and worsening heart failure. Although it is still controversial whether coronary spasm or microvascular spasm might contribute to the myocardial fibrosis, ACh-provocation test could provide a detailed pathophysiology of LV dysfunction with nonobstructive CAD, and might be useful to determine therapeutic strategy in patients with unknown cause of LV dysfunction.

Significance of microvascular spasm in nonobstructive coronary artery disease

The coronary arterial tree consists of not only the epicardial coronary arteries, but also smaller arteries and arterioles (<500 μm). The latter feed the capillaries and play an important role in the coronary microcirculation, being the main site of regulation of myocardial blood flow [113, 118, 119]. Epicardial coronary arteries without significant stenosis can contribute only about 5% of total coronary resistance, suggesting that coronary microvessels can play an important role in regulating myocardial vessels [25]. The importance of microvascular function has been recognized because patients with impaired microvascular function had worse outcomes following cardiovascular events than those with normal microvascular function [76, 120–123].

Modalities for diagnosing obstructive CAD such as CAG or CTA have improved remarkably. However, in patients with suspected angina, we can sometimes see both nonobstructive epicardial coronary arteries and non-ACh-provoked epicardial coronary spasm. Nonobstructive CAD has included not only angina with epicardial coronary spasm but also microvascular spasm or dysfunction [5–7, 62, 120, 121, 124] (Fig. 1). The prevalence of microvascular spasm or dysfunction in patients with nonobstructive CAD is unknown even after exclusion of epicardial coronary spasm [4, 10, 62, 118, 125]. One of the reasons may be because we have no standard diagnostic criteria for microvascular spasm or dysfunction.

We previously reported the possibility of diagnosing microvascular spasm or dysfunction by a combination of intracoronary ACh-provocation test, simultaneous measurement of myocardial lactate production, quantitative CBF, and ATP-CFR in patients with suspected angina with nonobstructive CAD [4] (Fig. 5). We defined microvascular spasm as meeting both of the following 2 criteria: (1) positive for myocardial lactate production and (2) decreased CBF during ACh-provocation test in patients with suspected angina and non-ACh-provoked epicardial coronary spasm. We defined microvascular dysfunction as meeting both of the following two criteria: (1) negative for myocardial lactate production and (2) decreased ATP-CFR. We categorized those patients with microvascular dysfunction to the unclassified ischemic heart disease (IHD) group. In this report, among 154 patients with suspected angina having non-ACh-provoked epicardial coronary spasm (with 47/154 [31%] male, 107/154 [69%] female), microvascular spasm was observed in 50/154 (32%) of patients (with 5/50 [10%] males, 45/50 [90%] females), and microvascular dysfunction (unclassified IHD) was observed in 32/154 (21%) of patients (with 9/32 [28%] males, 23/32 [72%] females). Some previous reports showed that during the ACh-provocation test, the coronary blood supply (as determined by quantitative CBF with an intracoronary doppler-tipped guidewire [FloWire]) could be associated with microvascular function [4, 62, 118, 126–133]. The ACh-provocation test can be useful to assess the reactivity (such as spasm) of not only of epicardial coronary arteries but also endothelium-dependent...
coronary microvessels. In addition, ATP-CFR is a tool to test the non-endothelium-dependent coronary artery reactivity and can be useful to assess the microvascular function in nonobstructive CAD [4, 63, 127, 128, 134]. Using several modalities during the ACh-provocation test, such as measurement of CBF, myocardial lactate production, and ATP-CFR, we can assess several types of nonobstructive CAD such as epicardial coronary spasm, microvascular spasm, and microvascular dysfunction in the suspected angina patients with nonobstructive CAD in routine clinical cardiovascular practice (Fig. 5).

Our report mentioned above [4] of the 154 patients with suspected angina and non-ACh-provoked epicardial coronary spasm showed that female sex, a lower body mass index, minor-borderline ischemic ECG changes at rest, limited baseline diastolic-to-systolic velocity ratio of CBF, and attenuated ATP-CFR were significantly associated with microvascular spasm. In this report, the prevalence of microvascular spasm (50/154, 32%) was higher in females than males (with 45/50 [90%] vs 5/50 [10%], respectively), and the average age and body mass index of patients with microvascular spasm were 62.7 ± 10.6 years and 22.3 ± 2.9 kg/m², respectively. These clinical features of the microvascular spasm, such as female sex, middle age, and low body mass index, are reminiscent of postmenopausal phenomena, which invites speculation of an association between the pathogenesis of microvascular spasm and age-dependent estrogen deficiency in those patients.
Limitations and complications in ACh-provocation test

The ACh-provocation test has several limitations. The ACh-provocation test cannot provoke coronary spasm in all patients with coronary spasm, although our previous study showed high sensitivity and specificity of the test in patients with variant angina [20, 21]. In patients with chronic kidney disease, the use of contrast medium during ACh-provocation test can have adverse effects. Radiation exposure during the test can be increased because of multiple procedures of the ACh-provocation test [56]. Finally, the ACh-provocation test is not recommended if the patient has severe bronchial asthma [56, 135].

ACh-provocation test has several potential complications. In our institution, the number of life-threatening arrhythmias during ACh-provocation test was 9 (0.5%) of 1637 patients who underwent this test [54]. A previous report showed that the number of serious major complications, such as sustained ventricular tachycardia, cardiac tamponade, and shock, was 4 (0.6%) of 715 patients during ACh-provocation test, but with no deaths occurring [55]. Other reports also showed that the incidence of complications during ACh-provocation test can be low [6, 8, 24, 53, 58, 59, 74, 136]. Coronary spasm induced by ACh-provocation test can be susceptible to spontaneous amelioration because the pharmacological effect of ACh is short [9, 22]. Based on these observations, ACh-provocation test can be a safe method, although it should be performed carefully.

Compliance with ethical standards

Conflict of interest Dr. Kaikita has received significant research grant support from Bayer Yakuhin, Ltd., Daiichi Sankyo Co., Ltd., and has received Honoraria from Bayer Yakuhin, Ltd. and Daiichi Sankyo Co., Ltd. Dr. Tsujita has received honoraria from Amgen Astellas BioPharma K.K., Kowa Pharmaceutical Co. Ltd., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Pfizer Japan Inc., Bristol-Myers K.K., and MSD K.K.; trust research/joint research funds from Bristol-Myers K.K., Sugi Bee Garden Co., LTD., and Kowa Pharmaceutical Co. Ltd.; and grants from ITI Co., Ltd., Abbott Medical Japan L.L.C., Abbott Vascular Japan Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Cardinal Health Japan, Kaneka Medix Co., Ltd., Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma, Chugai Pharmaceutical Co., Ltd., TERUMO Co., Ltd., NIPRO CORPORATION, NIHON KOHDEN CORPORATION, Medtronic Japan Co., Ltd., Japan Lifeline Co., Ltd., Fides-One, Inc., Fukuda Denchi Co., Ltd., and Boston Scientific Japan K.K.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. This article is protected by copyright. All rights reserved.

Conclusions and future perspectives

As summarized in this review, ACh-provocation test can be a safe and reliable method not only to diagnose epicardial coronary spasm but also to assess the pathophysiology of nonobstructive CAD. The ACh-provocation test is not often performed in routine clinical cardiovascular practice because multiple procedures of this test are required. However, the pathophysiology showed by ACh-provocation test can be associated with prognosis in patient with nonobstructive CAD. We can identify the high-risk patient with coronary spasm or microvascular spasm diagnosed by ACh-provocation test and treat with intensive care for the patients.

We hope that cardiologists will routinely perform the ACh-provocation test to assess the pathophysiology of nonobstructive CAD.

References

1. Waterbury TM, Tarantino G, Vogel B, Mehran R, Gersh BJ, Gulati R. Non-atherosclerotic causes of acute coronary syndromes. Nat Rev Cardiol. 2020;17:229–41.
2. Patel MR, Peterson ED, Dai D, et al. Low diagnostic yield of elective coronary angiography. N Engl J Med. 2010;362:886–95.
3. Phan A, Shufelt C, Merz CN. Persistent chest pain and no obstructive coronary artery disease. JAMA. 2009;301:1468–74.
4. Ohba K, Sugiyama S, Sumida H, et al. Microvascular coronary artery spasm presents distinctive clinical features with endothelial dysfunction as nonobstructive coronary artery disease. J Am Heart Assoc. 2012;1:e002485.
5. Tamis-Holland JE, Jnicel H, Reynolds HR, et al. Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease: a scientific statement from the American Heart Association. Circulation. 2019;139:e891–908.
6. Montone RA, Niccoli G, Fracassi F, et al. Patients with acute myocardial infarction and non-obstructive coronary arteries: safety and prognostic relevance of invasive coronary provocative tests. Eur Heart J. 2018;39:91–8.
7. Kaski JC. Provocative tests for coronary artery spasm in MINOCA: necessary and safe? Eur Heart J. 2018;39:99–101.
8. Ong P, Athanasiadis A, Borgulya G, et al. Clinical usefulness, angiographic characteristics, and safety evaluation of intracoronary acetylcholine provocation testing among 921 consecutive white patients with unobstructed coronary arteries. Circulation. 2014;129:1723–30.

Funding None.
9. Kinlay S. Coronary artery spasm as a cause of angina. Circulation. 2014;129:1717–9.
10. Ong P, Athanasiadis A, Borgulya G, Mahrholdt H, Kaski JC, Sechtem U. High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries. The ACOVA Study (Abnormal Coronary Vasomotion in patients with stable angina and unobstructed coronary arteries). J Am Coll Cardiol. 2012;59:655–62.
11. Ong P, Athanasiadis A, Hill S, Vogelsberg H, Voehringer M, Sechtem U. Coronary artery spasm as a frequent cause of acute coronary syndrome: the CASPAR (coronary artery spasm in patients with acute coronary syndrome) Study. J Am Coll Cardiol. 2008;52:523–7.
12. Tsujita K, Miyazaki T, Kaikita K, et al. Premenopausal woman with acute myocardial infarction caused by spontaneous coronary artery dissection and potential association with coronary vasospasm. Cardiovasc Interv Ther. 2012;27:121–6.
13. Sandoval Y, Jaffe AS. Type 2 myocardial infarction: JACC review topic of the week. J Am Coll Cardiol. 2019;73:1846–60.
14. Thygensen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Circulation. 2018;138:e618–51.
15. Sato K, Takahashi J, Odaka Y, et al. Clinical characteristics and long-term prognosis of contemporary patients with vasospastic angina: ethnic differences detected in an international comparative study. Int J Cardiol. 2019;291:13–8.
16. Beltrame JF, Crea F, Kaski JC, et al. International standardization of diagnostic criteria for vasospastic angina. Eur Heart J. 2017;38:2565–8.
17. Matsuzawa Y, Sugiyama S, Sugamura K, et al. Digital assessment of endothelial function and ischemic heart disease in women. J Am Coll Cardiol. 2010;55:1688–96.
18. Sato R, Sakamoto K, Kaikita K, et al. Long-term prognosis of patients with myocardial infarction type 1 and type 2 with and without involvement of coronary vasospasm. J Clin Med. 2020;9:1686.
19. Nakayama N, Kaikita K, Fukunaga T, et al. Clinical features and prognosis of patients with coronary spasm-induced non-ST-segment elevation acute coronary syndrome. J Am Heart Assoc. 2014;3:e000795.
20. Okumura K, Yasue H, Matsuyama K, et al. Sensitivity and specificity of intracoronary injection of acetylcholine for the induction of coronary artery spasm. J Am Coll Cardiol. 1988;12:883–8.
21. Okumura K, Yasue H, Horio Y, et al. Multivessel coronary spasm in patients with variant angina: a study with intracoronary injection of acetylcholine. Circulation. 1988;77:535–42.
22. Yasue H, Horio Y, Nakamura N, et al. Induction of coronary artery spasm by acetylcholine in patients with variant angina: possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm. Circulation. 1986;74:955–63.
23. Horio Y, Yasue H, Rokutanda M, et al. Effects of intracoronary injection of acetylcholine on coronary arterial diameter. Am J Cardiol. 1986;57:984–9.
24. Yasue H, Mizuno Y, Harada E. Coronary artery spasm—clinical features, pathogenesis and treatment. Proc Jpn Acad Ser B. 2019;95:53–66.
25. JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2013). Circ J. 2014;78:2779–801.
26. Yasue H, Nakagawa H, Itoh T, Harada E, Mizuno Y. Coronary artery spasm—clinical features, diagnosis, pathogenesis, and treatment. J Cardiol. 2008;51:2–17.
27. Yasue H, Kugiyama K. Coronary spasm: clinical features and pathogenesis. Intern Med. 1997;36:760–5.
28. Maseri A, Davies G, Hackett D, Kaski JC. Coronary artery spasm and vasoconstriction. The case for a distinction. Circulation. 1990;81:1983–91.
49. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109–42.

50. Yasue H, Matsuyama K, Matsuyama K, Okumura K, Morikami Y, Ogawa H. Responses of angiographically normal human coronary arteries to intracoronary injection of acetylcholine by age and segment. Possible role of early coronary atherosclerosis. Circulation. 1990;81:482–90.

51. Puchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373–6.

52. Okumura K, Yasue H, Matsuyama K, et al. Diffuse disorder of coronary artery vasomotility in patients with coronary spastic angina. Hyperreactivity to the constrictor effects of acetylcholine and the dilator effects of nitroglycerin. J Am Coll Cardiol. 1996;27:45–52.

53. Sueda S, Kohno H. Overview of complications during pharmacological spasm provocation tests. J Cardiol. 2016;68:1–6.

54. Sato K, Kaikita K, Nakayama N, et al. Coronary vasomotor response to intracoronary acetylcholine injection, clinical features, and long-term prognosis in 873 consecutive patients with coronary spasm: analysis of a single-center study over 20 years. J Am Heart Assoc. 2013;2:e000227.

55. Sueda S, Saeki H, Otani T, et al. Major complications during spasm provocation tests with an intracoronary injection of acetylcholine. Am J Cardiol. 2000;85(391–4):a10.

56. Sueda S, Kohno H, Ochi T, Uraoka T, Tsunemitsu K. Overview of the pharmacological spasm provocation test: Comparisons between acetylcholine and ergonovine. J Cardiol. 2017;69:57–65.

57. Friedberg CK. Some comments and reflections on changing interests and new developments in angina pectoris. Circulation. 1972;46:1037–47.

58. Ciliberti G, Seshasai SRK, Ambrosio G, Kaski JC. Safety of provocative tests of coronary artery spasm. Int J Cardiol. 2017;244:77–83.

59. Takagi Y, Yasuda S, Takahashi J, et al. Clinical implications of provocation tests for coronary artery spasm: safety, arrhythmia complications, and prognostic impact: multicentre registry study of the Japanese Corona Spasm Association. Eur Heart J. 2013;34:252–4.

60. Maseri A. Safety of provocative tests of coronary artery spasm and prediction of long-term outcome: need for an innovative clinical research strategy. Eur Heart J. 2013;34:252–4.

61. Sueda S, Ochi N, Kawada H, et al. Frequency of provoked coronary vasospasm in patients undergoing coronary arteriography with spasm provocation test of acetylcholine. Am J Cardiol. 1999;83:1186–90.

62. Ford TJ, Rocchiccioli P, Good R, et al. Systemic microvascular dysfunction in microvascular and vasospastic angina. Eur Heart J. 2018;39:4086–97.

63. Kochwade K, Bairey Merz CN. Microvascular coronary dysfunction in women: pathophysiology, diagnosis, and management. Curr Probl Cardiol. 2011;36:291–318.

64. Scanlon PJ, Faxon DP, Audet AM, et al. ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol. 1999;33:1756–824.

65. Doucette JW, Corl PD, Payne HM, et al. Validation of a Doppler guide wire for intravascular measurement of coronary artery flow velocity. Circulation. 1992;85:1899–911.

66. Sun H, Fukumoto Y, Ito A, Shimokawa H, Sunagawa K. Coronary microvascular dysfunction in patients with microvascular angina: analysis by TIMI frame count. J Cardiovasc Pharmacol. 2005;46:622–6.

67. Mohri M, Koyanagi M, Egashira K, et al. Angina pectoris caused by coronary microvascular spasm. Lancet. 1998;351:1165–9.

68. Ishida T, Hirata K, Sakoda T, et al. 5-HT1Dbeta receptor mediates the supersensitivity of isolated coronary artery to serotonin in variant angina. Chest. 1998;113:243–4.

69. Hackett D, Larkin S, Chierchia S, Davies G, Kasic JC, Maseri A. Induction of coronary artery spasm by a direct local action of ergonovine. Circulation. 1987;75:577–82.

70. Sueda S, Fujimoto K, Sasaki Y, et al. Differential incidence and morphology of provoked spasm between intracoronary acetylcholine and ergonovine testing: recommendation of supplementary use. Heart Vessels. 2019;34:745–54.

71. Sueda S, Kohno H, Fukuda H, et al. Induction of coronary artery spasm by two pharmacological agents: comparison between intracoronary injection of acetylcholine and ergonovine. Coron Artery Dis. 2003;14:451–7.

72. Kanazawa K, Suehara M, Ishida T, et al. Disparity between serotonin- and acetylcholine-provoked coronary artery spasm. Clin Cardiol. 1997;20:146–52.

73. Suzuki Y, Tokunaga S, Ikeuchi S, et al. Induction of coronary artery spasm by intracoronary acetylcholine: comparison with intracoronary ergonovine. Am Heart J. 1992;124:39–47.

74. Sueda S, Kohno H, Ochi T, Uraoka T. Overview of the acetylcholine spasm provocation test. Clin Cardiol. 2015;38:430–8.

75. Bairey Merz CN, Pepine CJ, Shimokawa H, Berry C. Treatment of coronary microvascular dysfunction. Cardiovasc Res. 2020;116:586–70.

76. Takahashi J, Nihei T, Takagi Y, et al. Prognostic impact of chronic nitrate therapy in patients with vasospastic angina: multicentre registry study of the Japanese coronary spasm association. Eur Heart J. 2015;36:228–37.

77. Takagi Y, Takahashi J, Yasuda S, et al. Prognostic stratification of patients with vasospastic angina: a comprehensive clinical risk score developed by the Japanese Coronary Spasm Association. J Am Coll Cardiol. 2013;62:1144–53.

78. Takagi Y, Yasuda S, Tsunoda R, et al. Clinical characteristics and long-term prognosis of vasospastic angina patients who survived out-of-hospital cardiac arrest: multicenter registry study of the Japanese Coronary Spasm Association. Circ Arrhythm Electrophysiol. 2011;4:295–302.

79. Pristipino C, Beltrame JF, Finocchiaro ML, et al. Major racial differences in coronary constrictor response between Japanese and Caucasians with recent myocardial infarction. Circulation. 2000;101:1102–8.

80. Beltrame JF, Sasayama S, Maseri A. Racial heterogeneity in coronary artery vasomotor reactivity: differences between Japanese and Caucasian patients. J Am Coll Cardiol. 1999;33:1442–52.

81. Koizumi T, Yokoyama M, Namikawa S, et al. Location of focal vasospasm provoked by ergonovine maleate within coronary arteries in patients with vasospastic angina pectoris. Am J Cardiol. 2006;97:1322–5.

82. Sueda S, Kohno H, Fukuda H, et al. Limitations of medical therapy in patients with pure coronary spastic angina. Chest. 2003b;123:380–6.

83. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014a;64:e139–228.

84. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014b;130:e444–426.
85. Tateishi K, Saito Y, Kitahara H, et al. Safety and usefulness of acetylcholine provocation test in patients with no culprit lesions on emergency coronary angiography. Int J Cardiol. 2018;269:27–30.

86. Kaikita K, Ishii M, Sato K, et al. Determinants of myocardial lactate production during acetylcholine provocation test in patients with coronary spasm. J Am Heart Assoc. 2015;4:e002387.

87. Tsujita K, Kaikita K, Araki S, et al. In Vivo optical coherence tomography visualization of intraplaque neovascularization at the site of coronary vasospasm: a case report. BMC Cardiovasc Disord. 2016;16:235.

88. Tsujita K, Sakamoto K, Kojima S, et al. Coronary plaque component in patients with vasospastic angina: a virtual histology intravascular ultrasound study. Int J Cardiol. 2013;168:2411–5.

89. Miyao Y, Kugiyama K, Kawano H, et al. Diffuse intimal thickening of coronary arteries in patients with coronary spastic angina. J Am Coll Cardiol. 2000;36:432–7.

90. Suzuki H, Kawai S, Aizawa T, et al. Histological evaluation of coronary plaque in patients with variant angina: relationship between vasospasm and neo-intimal hyperplasia in primary coronary lesions. J Am Coll Cardiol. 1999;33:198–205.

91. Kuga T, Tagawa H, Tomaiko H, et al. Role of coronary artery spasm in progression of organic coronary stenosis and acute myocardial infarction in a swine model. Importance of mode of onset and duration of coronary artery spasm. Circulation. 1993;87:573–82.

92. Ishii M, Kaikita K, Sato K, et al. Impact of aspirin on the progression of coronary arteries in patients with coronary spasm without significant atherosclerotic stenosis. Int J Cardiol. 2016;220:328–32.

93. Ishii M, Kaikita K, Sato K, et al. Impact of statin therapy on clinical outcome in patients with coronary spastic angina. J Am Heart Assoc. 2016;5:e003426.

94. Yasue H, Mizuno Y, Harada E, et al. Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers. J Am Coll Cardiol. 2008;51:1742–8.

95. Nishijima T, Nakayama M, Yoshimura M, et al. The endothelial nitric oxide synthase gene -786T/C polymorphism is a predictive factor for reattacks of coronary spasm. Pharmacogenet Genom. 2007;17:581–7.

96. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101:1899–906.

97. Yasue H, Takizawa A, Nago M, et al. Long-term prognosis for patients with variant angina and influential factors. Circulation. 1988;78:1–9.

98. Walling A, Waters DD, Miller DD, Roy D, Pelletier GB, Theroux P. Long-term prognosis of patients with variant angina. Circulation. 1987;76:990–7.

99. Nishizawa S, Shiraishi J, Torii S, et al. Intermediate fixed coronary artery stenosis at the site of ergonovine-provoked spasm as a predictor of long-term major adverse cardiac events of patients with coronary spastic angina. Circ J. 2009;73:699–704.

100. Sara JD, Lerman LO, Lerman A. The hyperactive lesion, beyond anatomy. J Am Coll Cardiol. 2015;66:1116–8.

101. Ishii M, Kaikita K, Sato K, et al. Acetylcholine-provoked coronary spasm at site of significant organic stenosis predicts poor prognosis in patients with coronary vasospastic angina. J Am Coll Cardiol. 2015;66:1105–15.

102. Ito S, Ohmori H. Subclinical very late thrombus formation inside and outside the everolimus-eluting stent implanted 3 years prior in a patient with provoked coronary spasm. Cardiovasc Interv Ther. 2017;32:72–6.

103. Hokimoto S, Tabata N, Sueta D, et al. The real-world prevalence of cardiovascular events related to coronary spasm after percutaneous coronary intervention. J Cardiol. 2016;68:20–8.

104. Hokimoto S, Mizuno Y, Sueta D, et al. High incidence of coronary spasm after percutaneous coronary interventions: comparison between new generation drug-eluting stent and bare-metal stent. Int J Cardiol. 2015;182:171–3.

105. Takeda M, Shiba N, Takahashi J, Shimokawa H. A case report of very late stent thrombosis with peri-stent coronary artery aneurysm and stent-related coronary vasospasm. Cardiovasc Interv Ther. 2013;28:272–8.

106. Maekawa K, Kawamoto K, Fuke S, et al. Images in cardiovascular medicine. Severe endothelial dysfunction after sirolimus-eluting stent implantation. Circulation. 2006;113:e850–1.

107. Kim JW, Park CG, Seo HS, Oh DJ. Delayed severe multivessel spasm and aborted sudden death after Taxus stent implantation. Heart. 2005;91:e15.

108. Caramori PR, Lima VC, Seidelin PH, Newton GE, Parker JD, Adelman AG. Long-term endothelial dysfunction after coronary artery stenting. J Am Coll Cardiol. 1999;34:1675–9.

109. Fuke S, Maekawa K, Kawamoto K, et al. Impaired endothelial vasomotor function after sirolimus-eluting stent implantation. Cire J. 2007;71:220–5.

110. Hofma SH, van der Giessen WJ, van Dalen BM, et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J. 2006;27:166–70.

111. Nakayama M, Yamamuro M, Takashio S, et al. Late gadolinium enhancement on cardiac magnetic resonance imaging is associated with coronary endothelial dysfunction in patients with dilated cardiomyopathy. Heart Vessels. 2018;33:393–402.

112. Uemura T, Yamamuro M, Kaikita K, et al. Late gadolinium enhancement on cardiac magnetic resonance predicts coronary vasomotor abnormality and myocardial lactate production in patients with chronic heart failure. Heart Vessels. 2016;31:1969–79.

113. Herrmann J, Kaski JC, Lerman A. Coronary microvascular dysfunction: evaluation by Doppler echocardiography. J Am Coll Cardiol. 2006;48:548–51.

114. Cannon RO 3rd. Microvascular angina and the continuing dilemma of chest pain with normal coronary angiograms. J Am Coll Cardiol. 2009;54:877–85.

115. Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: from mystery to reality. Eur Heart J. 2012;33:2771–2782b.

116. Yoon YS, Uchida S, Masuo O, et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation. 2005;111:2073–85.

117. Bolognese L, Carrabba N, Parodi G, et al. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation. 2004;109:1121–6.

118. Ong P, Camici PG, Beltrame JF, et al. International standardization of diagnostic criteria for microvascular angina. Int J Cardiol. 2018;250:16–20.

119. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med. 2007;356:830–40.

120. Taqueti VR. Coronary microvascular dysfunction in vasospastic angina: provocative role for the microcirculation in macrovessel disease prognosis. J Am Coll Cardiol. 2019;74:2361–4.

121. Suda A, Takahashi J, Hao K, et al. Coronary functional abnormalities in patients with angina and nonobstructive coronary artery disease. J Am Coll Cardiol. 2019;74:2350–60.

122. Lanza GA, Crea F. Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management. Circulation. 2010;121:2317–25.
123. Johnson BD, Shaw LJ, Pepine CJ, et al. Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: results from the NIH-NHLBI-sponsored Women's Ischaemia Syndrome Evaluation (WISE) study. Eur Heart J. 2006;27:1408–15.
124. Tanabe Y, Yoneyama K, Izumo M, Kongoji K, Harada T, Akashi YJ. A case of coronary microvascular spasm with slow flow induced by the intracoronary acetylcholine provocation test. Cardiovasc Interv Ther. 2015;30:372–6.
125. Reis SE, Holubkov R, Conrad Smith AJ, et al. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. Am Heart J. 2001;141:735–41.
126. Hirakawa K, Yamamuro M, Uemura T, et al. Correlation between microvascular dysfunction and B-type natriuretic peptide levels in non-ischemic heart failure patients with cardiac fibrosis. Int J Cardiol. 2017;228:881–5.
127. Yamanaka K, Tsujita K, Komura N, et al. Single-wire pressure and flow velocity measurement for quantifying microvascular dysfunction in patients with coronary vasospastic angina. Am J Physiol Heart Circ Physiol. 2015a;308:H478–84.
128. Yamanaka K, Tsujita K, Komura N, et al. Physiological basis of discordance between coronary flow velocity reserve and hyperemic microvascular resistance for evaluating coronary microvascular dysfunction in patients without atherosclerotic obstruction. Int J Cardiol. 2015b;201:535–7.
129. Camici PG, Crea F. Microvascular angina: a women’s affair? Circ Cardiovasc Imaging. 2015;8:e003252.
130. Takashio S, Yamamuro M, Izuimi Y, et al. Coronary microvascular dysfunction and diastolic load correlate with cardiac troponin T release measured by a highly sensitive assay in patients with nonischemic heart failure. J Am Coll Cardiol. 2013;62:632–40.
131. Inobe Y, Kugiyama K, Morita E, et al. Role of adenosine in pathogenesis of syndrome X: assessment with coronary hemodynamic measurements and thallium-201 myocardial single-photon emission computed tomography. J Am Coll Cardiol. 1996;28:890–6.
132. Rahman H, Ryan M, Lumley M, et al. Coronary microvascular dysfunction is associated with myocardial ischemia and abnormal coronary perfusion during exercise. Circulation. 2019;140:1805–16.
133. Fearn WF, De Bruyne B. The shifting sands of coronary microvascular dysfunction. Circulation. 2019;140:1817–9.
134. Takae M, Yamamoto E, Fujisue K, et al. Coronary blood flow volume change is negatively associated with platelet aggregability in patients with non-obstructive ischemic heart disease who have no anti-platelet agents. Int J Cardiol. 2019;277:3–7.
135. Haruta S, Okayama M, Uchida T, Hirosawa K, Kaskanuki H. Airway hyperresponsiveness in patients with coronary spastic angina: relationship between coronary spasticity and airway responsiveness. Circ J. 2007;71:234–41.
136. Saito Y, Kitahara H, Shoji T, et al. Intracoronary acetylcholine provocation testing- omission of the 20-microg dose is feasible in patients without coronary artery spasm in the other coronary artery. Circ J. 2016;80:1820–3.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.